TVM Capital Life Science closes new fund with USD 478 million
Munich — International law firm Clifford Chance has advised venture capital investor TVM Capital Life Science on the significantly oversubscribed closing of its TVM Life Science Innovation II fund. At $478 million, the fund represents the company’s largest fund to date.
TVM, a leading life science venture capital firm in North America and Europe, provides venture capital to international biopharmaceutical, medical device and diagnostic companies in North America and Europe. The Company invests in companies that offer a visible and attractive exit strategy from the outset, with the aim of maximizing returns and generating significant liquidity for investors at an early stage.
With support from top-tier domestic and international investors, including Eli Lilly, other strategic investors, pension funds, endowments, funds of funds, asset managers and leading U.S. banks, as well as family offices from North and South America, Europe and South Korea, TVM closed its fund at a total of $478 million.
TVM was founded in 1983 and is internationally positioned with offices in Luxembourg and Canada as well as consulting offices in Germany and other locations.
Advisor TVM: Clifford Chance
The international Clifford Chance team for TVM was led by partner Sonya Pauls (Corporate/Private Equity, Munich).
About Clifford Chance
Clifford Chance, one of the world’s leading law firms, is present for its clients with around 3,400 legal advisors in all major business centers around the world.
In Germany, Clifford Chance is represented by around 300 lawyers, auditors, tax advisors and solicitors in Düsseldorf, Frankfurt am Main and Munich.